However, the CVD-REAL Nordic showed no significant difference of the new-onset AF associated with the use of dapagliflozin compared with dipeptidyl peptidase-4 inhibitor (DPP4i) or other glucose-lowering agents in T2DM patients in real-world practice [19, 20]. The gene discussed is DPP4; the disease is atrial fibrillation.